Analystreport

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) had its price target raised by analysts at Cantor Fitzgerald from $34.00 to $49.00. They now have a "buy" rating on the stock.

Supernus Pharmaceuticals, Inc.  (SUPN) 
Last supernus pharmaceuticals, inc. earnings: 2/25 04:40 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.supernus.com